MyCartis technology intro
From an idea to the Evalution™ product
EPFL – SV (for students of class on Reg. medicine/Microfluidic based Dx)
20. Oct. 2014
Didier Falconnet, [email protected], www.mycartis.net (/blog)
Context
• Rudi Pauwels, PhD in pharmacology and life-sciences star-entrepreneur on sabbatical in the lab of Philippe Renaud (EPFL)
• Can we leverage microtechnologies to develop better diagnostic tools?
• 2007 Rudi Pauwels, Philippe Renaud and Nader Donzel found Biocartis S.A. (EPFL, PSE)
2 MyCartis 2014
The ambition: Making healthcare personalized
• Diagnosing patients at the molecular level (beyond current test method)
• Diagnosis of complex diseases and response to treatments are often associated with multiple biomarkers with time-dependent signatures
• Multiplex (multiple biomarkers simultaneously, high information density)
• Rapid and cost effective (time to results, cost per data point)
• Easy to use technology yet flexible (limited skills required)
• Quantitative (measuring the response of a treatment for fine tuning the
dose – one example of personalized medicine)
3 MyCartis 2014
*DeciBio market report Feb. 2012
Strong development of Dx technologies
• IVD spent currently represents <1% of total WW healthcare spent (~$5.5T+), although results from these tests account for 60-70% of all treatment decisions*.
• The “one fits all” drug and dose is over
• Today, strong focus on diagnostics as it is a corner stone of personalized medicine
4 MyCartis 2014
From start-up to SME in just a few years
• 2007 Biocartis is founded on seed money (R. Pauwels) and develops initial concepts and demonstrations
• 2010 Biocartis (< 10 employees) acquires the “Apollo” program from Philips with a new round of investments
• 2014 Biocartis (~ 160 employees in CH and B), launch of the Idylla™ platform (PCR based, sample-in data-out)
Mycartis spins-out (~ 50 employees in CH and B, integration of Pronota NV) and launch Evalution™ platform (Multiplex biomarker analysis, RUO)
5 MyCartis 2014
Historically 2 platforms in the same company
• Idylla™ − Diagnostic samples in/result
out platform based on real time PCR
• Evalution™ − Multiplexed biomarker analysis
platform for research (and diagnostics)
MyCartis 2014 6
Requirements
• Multiplex
• Rapid
• Easy to use technology yet flexible
• Quantitative
+
• Sensitive and reproducible/robust
• Versatile
• Facilitating development of multiplexed assays
7
Multiplexing for “rich data”
8
• Traditional technologies measure one molecule per reaction
• Multiplexing enables measuring multiple molecules simultaneously
• Increased information density per sample volume
• A variety of multiplexing technologies have emerged in the past decade, each with its encoding strategy and limitations
Innovative solution for multiplexing
9
Functionalize with capture molecules
Aliquots to create master mix
Add master mix to microfluidic cartridge
• Our starting point was IP from memobead
• Barcoded fluorescent beads for multiplexed analysis
• Concept demonstrated but impractical for industrialization
• Development of a novel digitally encoded particles (foundation of MyCartis technology)
Evalution™ animation
10 MyCartis 2014
Digitally encoded microparticles
11
Production process from state-of-the-art semi-conductor industry
Digital encoding yields thousands of codes
Compatible with well-established surface chemistries
Activated of bio-functionalized microparticles
High reproducibility from monocristalline silicon
Ideal flat surface for 2D imaging
Aggregation of 1800+ pixels per single microparticle
Microparticle for high data quality
Fluorescence detection zone • >1800 pixels of data per microparticle • Uniform signal (2D surface) • No cross-talk between particles • Smart fluorescence data aggregation
Robust digital coding • Unambiguous • Stable • Quality control integrated • Simple to produce • On-the-fly decoding
Clean and well characterized materials • Crystalline silicon matrix • Well established and robust chemistry • High quality production processes
Microtechnology enabled surface features • Optical signal enhancement layers • Flow enhancing structures
12
MyCartis 2014
Evalution™ core components
MyCartis 2014 13
Encoded microparticles
Microfluidic assay plate
Microfluidic assay plate When high technology meets simplicity
Channel cross-section 400μm x 17μm
High-fidelity replication for planar arrangement of
microparticles ̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶ μm tolerance ̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶
Based on titerplate standard for full compatibility with
lab automation
Run up to 16 assays in batch or on different dates
Capacity of 150-plex per channel
Optimized environment for fast, reproducible, and
specific bindings
Getting more from less in miniaturized environment ̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶ μL range ̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶
14
Simple and robust cartridge, no moving parts (i.e. no valves)
Enables mass production by plastic injection
Particles are retained and allow repeated imaging of the reaction chamber
MyCartis 2014
Automated data sampling
15 MyCartis 2014
Visual aspect and software
Data are displayed real-time upon imaging
confidential 16 MyCartis 2014
Instrumentation
Bench top instrument with automated controls, separate microparticle loading station
Green laser optics for ultra sensitive and low noise fluorescence imaging
High pressure operation for robust fluidics
Three independent temperature zones from 25 to 95 °C for assay flexibility
Independent operation of the 16 reaction chambers
Real-time or end-point imaging
17 MyCartis 2014
Evalution is composed of 4 subsystems
• Optical: x-y-z scanning objective, 532 nm laser, CMOS cam. Bright-field and Fluorescence mode.
• Thermal: 3 independent temperature zones (25-95°C)
• Fluidic: common mode pressure with up to 2000 mbar differential pressure
• Software: real-time data analysis and dynamic control over assay environment
confidential 18 MyCartis 2014
Microfluidics for short assay times and quantitative results
19
• Reaction limited regime (biophysical ideal conditions)
• Not governed by diffusion
• Fluorescence dependent of concentration (in RLR)
• Short assay times minimized non-specific binding
Reaction limited regime
Mass transfer limited regime
Squires, Messinger and Manalis. Nat. Bio. 2008
Flow rate function of tot. #particles and DP
• Data for 500mbars and 25°C in PBST
20
1 mm loaded : 250 particles
• And many more features but outside scope of this presentation
21
Summary on technology intro
• Novel solution for biomarker analysis
− Multiplex robust encoding
− Flexible comp. with different workflows, dynamic control over assay env.
− Versatile different sample and analyte types
− Adaptable no batch required, short time to result
− Easy to use visual, real-time, no plate transfer, only 1 instrument
− Fast reaction limited regime in microfluidic channels
− Quantitative sensitive fluorescent readout
22
Looking back to the start…
• A (good) idea that solves a question, a problem or opens possibilities not though of before
• Be open and curious across disciplines, network
• Change is good !
• Be prepared for ups and downs, be flexible
• Team-up with the “right” people, identify trends
• We are now commercially launching our product with a CEO knowing the market very well.
23
Outlook
• Launch on Research market (now)
• IVD
• POC
• Matching sensitivities of digital systems
• Further simplifying workflow for super and hyperplexing
• Menu expansion for different disease areas (with partners)
• www.mycartis.net (/blog)
24
Thank you
25
MyCartis 2014 confidential
Flexible workflow and readout mode
• Traditional multiplex sandwich −endpoint (min. 5 pip. steps)
• Simple and fast coflow sample and det. Ab −kinetic or endpoint (1 pip. step)
• Post-PCR detection −kinetic or endpoint (1-3 pip. steps)
26
MyCartis 2014 confidential
Benefits of Evalution™ (and coflow)
• Labour − You save multiple pipetting steps
− No need to transfer plate between instruments
• Time − Great reduction of assay time
− Great reduction of hands on time
• Workspace − 1 instrument versus 3 instruments
• Reagents − Evalution uses differential air pressure for media transport
− No drive or sheath fluid needed
27
Immunoassay workflow drastically accelerated
− Simple workflow with minimal hands-on-time
− Real-time or end-point readout
− Identical workflow with increased plex-size
TAT: < 30 min
HOT: <10 min
5 pipet steps
Evalution
Seq Flow
TAT: 10 min
HOT: <5 min
2 pipet steps
TAT: > 2.5 h HOT: > 1h >15 pipet steps
ELISA platform
Incubate Read Preparation Incubate Wash Wash Incubate
0 60 120 180 240 min
TAT Turn Around Time HOT Hands-On Time
*Preparation for ELISA
includes performing multiple dilutions to enter dynamic range
*
Evalution
Co Flow
MyCartis 2014 confidential
Thermal subsystem:
• 3 different and independent temperature zones
29
Inlet zone
Denaturation zone
Detection zone
Prepare the reagents
• Couple capture molecules • Create a mix
1
Prepare the assay plate
• Loading of pre-mixed encoded microparticles
• Multiple channels at a time
2
Insert the plate
• Select assay parameters
• Edit/load protocol 3
Run the assay
• Load the sample • Monitor the reaction and report results
4
The workflow, 2 protocols
MyCartis 2014 confidential 30
Full flexibility for user-defined assay
Fast workflow with pre-filled assay plate